Table 3.
Patient characteristics at hospital admission for COVID-19, according to hospital outcome.
| Patients with hospital outcome, no. (%) | |||
|---|---|---|---|
| All (n = 167) | Patients discharged (n = 111)a | Patients who died (n = 56) | |
| Clinical features during admission | % shown as the proportion of “all” | ||
| Clinical severity | |||
| Mild | 26 (16) | 24 (92) | 2 (8) |
| Moderate–severe | 128 (77) | 85 (66) | 43 (34) |
| Critical | 13 (8) | 2 (15) | 11 (85) |
| Respiratory support | |||
| No supplemental oxygen | 39 (23) | 36 (92) | 3 (8) |
| Supplemental oxygen | 78 (47) | 56 (72) | 22 (28) |
| Noninvasive ventilation | 35 (21) | 13 (37) | 22 (63) |
| Invasive ventilation | 15 (9) | 6 (40) | 9 (60) |
| Laboratory measures at hospital admission | % shown as the proportion of “all” | ||
| Absolute neutrophil countb | |||
| Above median | 80 (50) | 46 (57) | 34 (43) |
| Below median | 79 (50) | 59 (75) | 20 (25) |
| Lymphocyte countc | |||
| Above median | 79 (50) | 57 (72) | 22 (28) |
| Below median | 78 (50) | 47 (60) | 31 (40) |
| Plateletsd | |||
| Above median | 77 (51) | 58 (75) | 19 (25) |
| Below median | 75 (49) | 44 (59) | 31 (41) |
| D-dimers | |||
| Above mediane | 67 (51) | 40 (60) | 27 (40) |
| Below medianf | 64 (49) | 50 (78) | 14 (22) |
| Ferriting | |||
| Above median | 41 (50) | 28 (68) | 13 (32) |
| Below median | 41 (50) | 32 (78) | 9 (22) |
| COVID-19 therapy | % shown as the proportion of “all” | ||
| (Hydroxy)chloroquine | 148 (89) | 101 (68) | 47 (32) |
| No (hydroxy)chloroquine | 19 (11) | 10 (53) | 9 (47) |
| Azithromycin | 91 (54) | 62 (68) | 29 (32) |
| No azithromycin | 76 (46) | 49 (64) | 27 (36) |
| Antiretrovirals | 103 (62) | 65 (63) | 38 (37) |
| No antiretrovirals | 64 (38) | 46 (72) | 18 (28) |
| Antiviral combination therapy | |||
| None | 11 (6) | 6 (55) | 5 (45) |
| (Hydroxy)chloroquine only | 16 (10) | 11 (69) | 5 (31) |
| (Hydroxy)chloroquine and retrovirals | 47 (28) | 30 (64) | 17 (36) |
| (Hydroxy)chloroquine and azithromycin | 34 (20) | 27 (79) | 7 (21) |
| (Hydroxy)chloroquine, azithromycin, and retrovirals | 51 (31) | 33 (65) | 18 (35) |
| Other combination therapy | 8 (5) | 4 (50) | 4 (50) |
| Steroids | 83 (50) | 51 (61) | 32 (39) |
| No steroids | 84 (50) | 60 (71) | 24 (29) |
| Anti-interleukin-6 receptor antibody therapy | 22 (13) | 15 (68) | 7 (32) |
| No anti-interleukin-6 receptor antibody therapy | 145 (87) | 96 (66) | 49 (34) |
| Steroids and anti-interleukin-6 receptor antibody therapyf | 21 (13) | 14 (67) | 7 (33) |
| No steroids and anti-interleukin-6 receptor antibody therapyf | 143 (87) | 95 (66) | 48 (34) |
| Heparin | 109 (65) | 77 (71) | 32 (29) |
| No heparin | 58 (35) | 34 (59) | 24 (41) |
COVID-19 coronavirus disease 2019, IQR interquartile range.
aIncludes one patient who remains hospitalized receiving ongoing care.
bData missing for eight patients, six who were discharged and two who died in hospital.
cData missing for 11 patients, 8 who were discharged and 3 who died in hospital.
dData missing for 16 patients, 10 who were discharged and 6 who died in hospital.
eData missing for 36 patients, 21 who were discharged and 15 who died in the hospital.
fData missing for 85 patients, 51 who were discharged and 34 who died in the hospital.
gData missing for three patients, two who were discharged and one who died in the hospital.